Literature DB >> 13242802

Purification and some properties of Clostridium welchii type A theta toxin.

F B ROTH, L PILLEMER.   

Abstract

Keywords:  CLOSTRIDIUM PERFRINGENS

Mesh：

Substances：

Year:  1955        PMID： 13242802

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  8 in total

1.  Toxin production by Clostridium perfringens. I. Synthesis of alpha- and theta-hemolysins, lecithinase and proteinase in a synthetic medium.

Authors:  J E ROBERTS
Journal:  J Bacteriol       Date:  1957-10       Impact factor: 3.490

2.  The histotoxic clostridial infections of man.

Authors:  J D MACLENNAN
Journal:  Bacteriol Rev       Date:  1962-06

3.  Haemolytic activity of the alpha and theta toxins of Clostridium welchii.

Authors:  J A Schulze; M Nakamura
Journal:  J Hyg (Lond)       Date:  1969-03

4.  Interaction of streptolysin O from Streptococcus pyogenes and theta-toxin from Clostridium perfringens with human fibroblasts.

Authors:  M Thelestam; R Möllby
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

5.  High-molecular-weight hemolysin of Clostridium tetani.

Authors:  K Mitsui; N Mitsui; K Kobashi; J Hase
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

6.  Excitatory effect of Clostridium perfringens alpha toxin on the rat isolated aorta.

Authors:  Y Fujii; S Nomura; Y Oshita; J Sakurai
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

7.  Fate of partially purified C-14-labeled toxin of Clostridium perfringens.

Authors:  P D ELLNER
Journal:  J Bacteriol       Date:  1961-08       Impact factor: 3.490

8.  BEC, a novel enterotoxin of Clostridium perfringens found in human clinical isolates from acute gastroenteritis outbreaks.

Authors:  Shinya Yonogi; Shigeaki Matsuda; Takao Kawai; Tomoko Yoda; Tetsuya Harada; Yuko Kumeda; Kazuyoshi Gotoh; Hirotaka Hiyoshi; Shota Nakamura; Toshio Kodama; Tetsuya Iida
Journal:  Infect Immun       Date:  2014-03-24       Impact factor: 3.441
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.